+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 6 Actively Recruiting clinical trials

O

Actively Recruiting

Researchers are studying the effects of orforglipron compared to a placebo in adults aged 50 and older who have atherosclerotic cardiovascular disease ASCVD andor chronic kidney disease CKD. This Phase 3 trial aims to evaluate how orforglipron impacts major cardiovascular events over about five years of participation. Participants will be randomly assigned to receive either orforglipron orally along with standard care or a placebo orally with standard care. The study is double-blind, meaning neither participants nor researchers know who receives the active drug or placebo. This design helps measure the drugs impact on cardiovascular health and kidney function over the study duration. During the study, participants will be monitored regularly to track the time to the first major cardiovascular event and other health outcomes such as kidney function changes and the onset of type 2 diabetes. The study involves ongoing assessments from baseline through the five-year period, including follow-ups to ensure safety and gather detailed health information.

Age: 50Years +All GendersPhase 3
566 locations
C

Actively Recruiting

Researchers are collecting detailed information about patients with venous thromboembolism VTE to improve understanding of this condition, especially in groups often excluded from clinical trials such as pregnant women, elderly patients, and those with severe health issues. This observational registry aims to provide data that can help reduce death rates, recurrences of blood clots, bleeding problems, and arterial events related to VTE. This study gathers clinical details about each patient, including other health conditions, and tracks the type, dose, duration, and results of antithrombotic treatments over the first three months. The registry is accessible online to assist doctors in managing complex cases by comparing patient profiles and identifying those at higher risk of complications. Participants clinical status and treatment outcomes are recorded, focusing on recurrence of VTE, bleeding events, and mortality over a three-year period. The information supports the creation of predictive scores to help healthcare providers identify patients at higher risk. The study started in 2001 and plans to continue until 2027, with ongoing data collection and follow-up.

All AgesAll Genders
305 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness of a remote monitoring software called Caaring in cancer patients undergoing outpatient oral cancer treatment. The study aims to see if using this self-management platform helps patients manage their illness better and reduces the number of in-person and telephone visits with specialized medical and nursing staff. This is a randomized, multicenter clinical trial comparing two groups of patients over 12 weeks. One group will use the Caaring app on their smartphones to report data and complete questionnaires related to their treatment and health. This group will also receive educational and prevention recommendations about cancer. The other group will receive routine medical follow-up visits without the remote monitoring app. Both groups will be observed for 12 weeks following their inclusion in the study. Participants will be monitored through the app or routine visits, with researchers collecting information on treatment adherence, completion of data, use of health resources, and patient satisfaction with the software. The main outcome is the percentage of adherence to prescribed treatment over 12 weeks. Secondary outcomes include data completion rates, changes in health resource use, and patient satisfaction. The study involves regular assessments and questionnaires, with a total participation duration of 12 weeks.

Age: 18Years +All GendersPhase Not Applicable
3 locations
N

Actively Recruiting

This research focuses on women aged 18 years or older who are hospitalized for their first episode of heart failure, regardless of their hearts ejection fraction. Women represent over half of heart failure hospital admissions but are often underrepresented in studies, especially concerning risk factors unique to women such as pregnancy complications and menopause timing. The study aims to describe the clinical and prognostic features of these women over a year and compare findings with a similar group of men to understand sex-specific differences better. Participants are enrolled at hospital discharge or within 15 days at a heart failure unit visit after their initial admission. The study does not assign treatments instead, all care decisions follow routine clinical practice. Women are followed for 12 months with visits scheduled at 3, 6, and 12 months. Data collected include detailed medical history, heart failure characteristics, treatments given, side effects, and social factors. Assessments include laboratory tests, heart imaging, and health status questionnaires. Throughout the study, participants undergo regular evaluations of their heart function, treatment tolerability, and overall health using standardized scales and questionnaires. Hospital visits and emergency care related to heart failure are tracked. Social and cognitive status, as well as quality of life, are assessed at the start and end of the study. The main outcome measured is whether participants experience death from any cause or worsening heart failure within 12 months. This comprehensive approach aims to improve understanding of heart failure in women.

Age: 18Years +FEMALE
24 locations
S

Actively Recruiting

Researchers aim to develop clear, universal definitions and standardized practices to diagnose and prevent ventilator-associated pneumonia VAP in newborns in neonatal intensive care units NICUs. This project involves creating evidence-based recommendations and best practice protocols for healthcare teams to improve and unify care and diagnosis across participating units. The study is observational and seeks to understand how these interventions reduce the frequency and impact of VAP in neonates undergoing invasive mechanical ventilation. The study involves several phases initially, researchers provide access to data collection forms and instructions to follow usual diagnostic criteria. Next, all NICU teams receive training on the evidence-based preventive measures and diagnostic criteria. Finally, these trained practices are incorporated into daily care routines. A surveillance registry collects data such as patient demographics, antibiotic use, clinical signs, and diagnostic tests related to VAP throughout invasive ventilation and a short monitoring period after extubation. Participants are newborns admitted to NICUs who require mechanical ventilation for at least 48 hours. Data collected includes clinical evaluations, radiological and microbiological tests, and antibiotic treatments. Researchers monitor how well preventive measures are implemented and track changes in VAP diagnosis and prevention. The main outcome measured is the impact of this multimodal intervention on VAP incidence from the start of ventilation until extubation plus two extra days in some cases. The study runs through multiple phases including training, data collection, and analysis over several years.

Age: 0Days - 6MonthsAll Genders
39 locations
P

Actively Recruiting

Researchers are evaluating the combination of 177Lu-DOTATATE Lutathera4 and the PARP inhibitor olaparib for treating children and adolescents with recurrent or relapsed solid tumors that express somatostatin receptors SSTR. These tumors typically have a poor prognosis, and while 177Lu-DOTATATE has been approved for certain adult neuroendocrine tumors, its use in children is still being explored. Combining 177Lu-DOTATATE with olaparib aims to enhance the treatment effect by preventing DNA repair in cancer cells, potentially leading to increased tumor cell death. The study is a single-arm, open-label Phase III trial administering up to four cycles of treatment. 177Lu-DOTATATE is given intravenously every 8 weeks at doses adjusted by age and body weight, along with intravenous fluids and amino acid infusions to protect the kidneys. Olaparib is taken orally twice daily from day 3 to day 28 of each 8-week cycle, with doses gradually increased according to a standard design. Treatment continues unless unacceptable side effects, disease progression, withdrawal, or death occur. Participants will undergo regular assessments including imaging to monitor tumor response, safety evaluations, and tests of organ function. Researchers will measure safety mainly through observations during the first 8 weeks and evaluate preliminary treatment activity up to 24 months. The study includes follow-up to assess longer-term safety, tolerability, and effectiveness of the drug combination in this young population.

Age: 3Years +All GendersPhase 1Phase 2
1 location